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1. Introduction 
Retinal vascular occlusions are serious diseases and significant causes of blindness that 
include arterial and venous obstructions. The causes, pathogenesis, clinical characteristics, 
prognosis, and response to therapy are influenced by the location of the occlusion in the 
retinal vasculature and by the extent of retinal nonperfusion. 
The hallmark of clinical presentation in the retinal occlusive disease is painless loss of 
vision, which can be asymptomatic, gradual with only mildly reduced visual acuity, or 
sudden and reduced to counting fingers depending on the extent of the irrigation area of the 
affected vessel. The clinical presentation aids in distinguishing the type of the occlusion, 
which may be classified according to the anatomical site of the occlusion.  
2. Retinal Artery Occlusion 
Retinal artery occlusion (RAO) represents an ophthalmologic emergency. In 1859, von 
Graefe first described central retinal artery occlusion (von Graefe, 1859). Retinal artery 
obstruction may be classified as follows: central (CRAO), affecting the retinal vessel at the 
optic nerve, hemicentral (occasional, only when one of the two trunks of the CRA is 
occluded) (Akkoyun et al., 2006; Karagoz et al., 2009; Schmidt & Kramer-Zucker, 2011), 
branch (BRAO), obstruction distally to the lamina cribrosa of the optic nerve, cilioretinal 
(CLRAO) and central sparing cilioretinal artery (Hayreh, 2011). Obstructions more proximal 
to the central retinal artery, in the ophthalmic artery, or even in the internal carotid artery, 
may produce visual loss as well. More proximal obstructions usually cause a more chronic 
form of visual problem—the ocular ischemic syndrome often associated with occlusive 
carotid disease (Kearns & Hollenhorst, 1963). 
Central retinal artery occlusion results in sudden visual loss and is therefore one of the most 
important topics in ophthalmology. Branch retinal artery occlusion causes sudden 
segmental visual loss and may recur to involve other branch retinal arterioles. Amaurosis 
fugax is a common transient acute retinal ischemic condition. Acute retinal arterial occlusive 
disorders together comprise one of the major causes of acute visual loss (Hayreh, 2011). 
Only anecdotal reports have described spontaneous recovery of vision, and case series have 
shown only up to 14% of spontaneous recovery (Atebara et al., 1995). 
The majority of retinal arterial obstructions are either thrombotic or embolic in nature (an 
embolus is visible only in 20% of the patients with branch or central retinal artery occlusion) 
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(Rumelt & Brown, 2003). Arterial occlusions in the eye are almost always due to 
microembolism and the major source of microemboli is the plaque(s), which may be present 
with or without any significant carotid artery stenosis. Thus, absence of significant stenosis 
of the carotid artery does not necessarily rule out the carotid artery as the source of 
microembolism (Hayreh et al., 2009). 
Immediate intervention improves chances of visual recovery, but even then, the prognosis is 
rather poor, with only 21-35% of eyes retaining useful vision (Jain & Juang, 2009), because it 
dominantly depends on the type of the occlusion (Hayreh & Zimmerman, 2005). Although 
restoration of vision is of immediate concern, retinal artery occlusion is a forerunner for 
other systemic diseases that must be evaluated promptly. Establishing of the cause of 
obstruction is essential. In case of giant cell arteritis causing occlusion immediate treatment 
is urgent. 
2.1 Epidemiology 
Central retinal artery obstruction (CRAO) is a rare event – it has been estimated to account 
for about 0.85 in 100,000 per year (Jain & Juang, 2009). The mean age at onset is about 60 
years, with a range from the first to the ninth decade of life (Duker, 2003). Bilateral 
obstruction occurs in 1-2% of cases (Brown, 1994). CRAOs account for 58% of acute RAOs, 
BRAOs for 38%, and cilioretinal artery occlusions (CLRAOs) (Jain & Juang, 2009). There are 
discrepancies among authors regarding the prevalence of men over women. Some advocate 
the ratio 2:1 (Duker, 2003) whereas the others found slightly more frequent occurrence in 
men (Hayreh et al., 2009). A large case series documented that approximately one fourth of 
patients with CRAO had a form with the cilioretinal sparing (Brown & Shields, 1979). The 
incidence of CLRA occlusion (CLRAO) varies in different studies from none to 32% (Justice 
& Lehmann 1976), which would be the most acceptable data, because the incidence was 
calculated by reviewing stereoscopic color fundus photographs as well as FA; the incidence 
of CLRAO is in direct proportion with the presence of cilioretinal artery in the population. 
FA is the most reliable way to ascertain the true incidence because the CLRA dyes 
concurrently with the filling of the choroid and usually before the start of filling of the CRA. 
The arteries occurred bilaterally in 14.6% (Justice & Lehmann, 1976). 
Multiple studies have shown increased mortality in patients with retinal arterial emboli 
(Bruno et al., 1995; Ho et al., 2008; Lindley et al., 2009). The frequency of retinal emboli 
increases with age and are more common in men than in women. Bilateral are rare, although 
multiple emboli in a single eye may be seen in up to one third of cases. They are associated 
with the presence of carotid artery disease (CAD), hypertension, smoking, and possibly 
diabetes (Wong & Klein, 2002). The large Beaver Dam Eye Study calculated the prevalence 
of retinal arteriolar emboli of 1.3% in the population ranged from 43-86 years, and the 5-year 
incidence of 0.9%, the 10-year incidence of 1.5% for the same population, and also confirmed 
a significantly higher hazard of dying from a stroke in people with retinal emboli (Klein et 
al., 1999; Klein et al., 2003). 
Debate exists in the literature on the prevalence and etiology of neovascularization (NV) 
following CRAO. The reported prevalence varies from 2.5% to 31.6%. Studies have reported 
prevalence of 18.2% of neovascularization and 15.2% of neovascular glaucoma (NVG) 
(Duker et al., 1991; Rudkin et al., 2010). In branch retinal artery occlusion, the incidence is 
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even rarer. Neovascularization is more likely to occur in persons with concurrent diseases 
and not CRAO per se, as with diabetes, severe carotid artery disease or generalized 
atherosclerosis (Hayreh & Podhajsky, 1982). Clinical cases have been reported in which 
neovascular glaucoma developed after branch retinal artery occlusion (Brown & Reber, 
1986); most probably they are a result of later complete CRAO rather than pure BRAO. 
2.2 Pathophysiology and histology 
Visual loss from retinal arterial occlusion (RAO) occurs from the loss of blood supply to the 
inner layer of the retina. Blood supply to the retina originates from the central retinal (CRA) 
and the cilioretinal (CLRA) artery. The primary source of blood supply to both arteries - the 
ophthalmic artery (OA), usually the first intracranial branch of the internal carotid artery 
(ICA), does not always originate from the ICA; the most common abnormal origin is the 
middle meningeal artery (Hayreh, 2011; Morandi et al., 1998). The central retinal artery 
arises independently in 37.5% from the ophthalmic artery, in 59.5% by a common trunk with 
one or another posterior ciliary artery (PCA), and extremely rarely with other branches of 
the OA. Numerous anastomoses are established by the branches of the CRA with other 
branches of the OA, mostly pial. The study showed that these pial anastomoses were 
usually large enough to establish a variable amount of collateral circulation in the eye 
having an occlusion of the CRA. This was also demonstrated by fluorescein fundus 
angiography (FA) (Hayreh, 2011; Hayreh & Weingeist, 1980). The central retinal artery 
supplies the retina as it branches into smaller segments upon leaving the optic disc. The so-
called “branch retinal arteries” are in fact arterioles after the first branching in the retina 
which don’t have either an internal elastic lamina or a continuous muscular layer (Hayreh, 
2011). A retinal vascular bed does not own any anastomoses; it is end-arterial system. The 
cilioretinal artery belongs to the PCA system; it usually originates from the peripapillary 
choroid or directly from one of the PCAs and supplies the part of the macular retina. The 
CLRA has a characteristic hook-like appearance at its site of entry into the retina at the optic 
disc margin, usually on the temporal side. Branch retinal artery occlusion (BRAO) occurs 
when the embolus lodges in a more distal branch of the retinal artery. BRAO typically 
involves the temporal retinal vessels and usually does not require treatment, unless 
perifoveolar vessels are threatened (Ho et al., 2008). 
Acutely, obstruction of the central retinal artery results in inner retinal layer edema and 
pyknosis of the ganglion cell nuclei. Ischemic necrosis results and the retina become 
opacified and yellow-white in appearance. The opacity is most dense in the posterior pole as 
a result of the increased thickness of the nerve fiber layer and ganglion cells in this region. 
The opacification takes as little as 15 minutes to several hours before becoming evident and 
resolves in 4-6 weeks. Furthermore, the foveola assumes a cherry-red spot because of a 
combination of 3 factors: (i) the intact retinal pigment epithelium and choroid underlying 
the fovea, (ii) the foveolar retina is nourished by the choriocapillaris, and (iii) the thinnest 
NFL at this location. The late stage shows a homogenous scar replacing the inner layer of the 
retina. Pigmentary changes are typically absent since the retinal pigment epithelium 
remains unaffected (Kearns & Hollenhorst, 1963).  
It has been shown experimentally on animal studies that the retinal damage is irreversible 
after 105 minutes of completely occluded circulation, but may recover at 97 minutes 
(Hayreh et al., 2004), and the treatment instituted at any time beyond 4h after the onset of 
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CRAO cannot have any scientific rationale for improvement of vision. However, complete 
occlusion or retinal artery circulation in humans is rare with retinal artery disease; thus, 
retinal recovery is possible even after days of ischemia (Brown & Magargal, 1988). 
Controversy exists regarding the optimal window of treatment in humans, but the 
conservative approach involves treatment up to 24 hours (Kearns & Hollenhorst, 1963).  
The retinal artery could be occluded due to embolism, vasoobliteration (atherosclerotic 
plaques, giant-cell arteritis and other types of vasculitis) and vascular compression (a 
retrobulbar mass - hematoma, neoplasm, retrobulbar injections may lead to an optic nerve 
and central retinal artery compression) (Korner-Stiefbold, 2001), angiospasm, hemodynamic 
or hydrostatic arterial occlusion (Hayreh, 2011). By far the most common cause of 
nonarteritic RAO is the embolism. Emboli are usually of three types: cholesterol - 
Hollenhorst plaque, platelet-fibrin, calcified, and occasionally myxomatous, or bacterial. The 
incidence is 74%, 15.5% and 10.5% for the first 3 types, respectively (Arruga & Sanders, 
1982). They are mostly of carotid and/or cardiac origin (Korner-Stiefbold, 2001). The major 
source of embolism in the carotid arteries is plaque (66%), whereas a significant carotid 
stenosis (>50%) accounts for only 30% of cases (Hayreh et al., 2009; Korner-Stiefbold, 2001; 
Younge, 1989). Statistically, Caucasians, when compared to African Americans, have 
significantly different incidence of ICA stenosis, which is 41% and 3.4% for the each group, 
respectively (Ahuja et al., 1999). A significant stenosis of the extracranial internal carotid 
artery is the most common identified condition associated with retinal and ocular ischemia 
(Biousse, 1997; Mizener et al., 1997; Sharma et al., 1998). It represents the hemodynamic 
cause, and, especially if associated with nocturnal arterial hypotension, can lead to transient 
CRAO (Hayreh & Zimmerman, 2005). The sources of emboli in heart are valvular lesions, 
patent foramen ovale, myxoma and endocarditis (Mangat, 1995; Reese & Shafer, 1978; 
Schmidt et al., 2005; Sharma et al., 1997). It must be remembered though, that the absence of 
any abnormality on color Doppler ultrasound or echocardiography does not exclude carotid 
artery or the heart as the source of microembolism, because of the test-resolution and 
location of the plaque/stenosis. 
Animal studies have shown that, serotonin in atherosclerotic vessels produces vasospasm of 
the central retinal artery (CRA) and/or posterior ciliary artery (PCA) in various 
combinations (but not vasospasm of the arterioles in the retina). It is postulated that in some 
atherosclerotic individuals this mechanism may play an important role in the development 
of ischemic disorders of the retina and optic nerve head (ONH), including amaurosis fugax, 
CRA occlusion and anterior ischemic optic neuropathy, and possibly also glaucomatous 
optic neuropathy, particularly in normal tension glaucoma (Hayreh, 1999). 
Central retinal arterial occlusions could be divided into permanent or transient; arteritic 
(usually gigantocellular arteritis) or nonarteritic occlusion. The transient is the nonarteritic 
and could occur due to (i) transient impaction of an embolus, (ii) fall of perfusion pressure 
in the retinal vascular bed below the critical level (night arterial hypotension, hypovolemic 
shock, hemodialysis, spasm of CRA, marked carotid artery disease, ocular ischemia, or a rise 
of intraocular pressure because of orbital swelling, acute angle-closure glaucoma, 
neovascular glaucoma (NVG) with ocular ischemia), and (iii) vasospasm of the 
atherosclerotic lesions (induced by the platelet-aggregation plaque secreting serotonin) 
(Hayreh, 2011). 
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Branch arterial occlusion is usually due to embolism and occasionally vasculitis. It could be 
recurrent (Barak et al., 1997; Beiran et al., 1995; Beversdorf et al., 1997; Johnson et al., 1994). 
Most of these cases probably have Susac’s syndrome (autoimmune endotheliopathy leading to 
encephalopathy, BRAO and hearing loss) (Susac et al., 2007). The etiology of this syndrome is 
still unknown, but the prognosis is good in most cases. Spontaneous resolution usually occurs, 
but early treatment minimizes the risk of sequelae (Van Winden & Salu, 2010). 
2.3 Causes 
Embolism of the carotid artery and the heart are the most common causes of retinal artery 
obstruction. Carotid artery disease causes retinal arterial occlusion by three mechanisms: 
embolism, hemodynamic changes in significantly stenosed carotid artery, and arterial 
spasm. The major source of emboli is plaques in the carotid arteries, and much less 
frequently stenosis. According to some studies, hemodynamically significant carotid artery 
stenosis was found in about 18%of patients with acute RAO (Sharma et al., 1998) and as 
previously mentioned, Hayreh et al. suggest that the presence of plaques on Doppler color 
imaging is of more value in determining the cause of acute occlusive event rather than the 
embolus itself (Hayreh, 2005). The probable cause is the microembolism, which may not 
produce hemodynamically significant stenosis recordable on Doppler color imaging but 
may indeed account for the retinal artery occlusion. As shown in the study, carotid Doppler 
and/or angiography showed the presence of plaques in 71% in CRAO and 66% in BRAO 
(Hayreh et al., 2009). The fluctuation of hemodynamic factors, especially drops in blood 
pressure in nocturnal hypotension along with significant stenosis of the carotid artery may 
be responsible for transient retinal artery occlusion (Hayreh & Zimmerman, 2005; 
McCullough et al., 2004). Based on experimental studies on animals, the investigators have 
introduced the possible role of serotonin, released by platelet aggregation on atherosclerotic 
plaques in the carotid artery, causing transient vasospasm of the central retinal artery and 
thus potentially inducing retinal artery occlusion and retinal ischemic disorders. 
Systemic cardiovascular diseases have a well known association with retinal arterial 
occlusive disease in elderly people (Sharma, 1998). Therefore, a careful history should 
include identifying the possible underlying causes such as arterial hypertension, diabetes 
mellitus, hyperlipidemia, carotid artery disease, coronary artery disease, cerebrovascular 
disease and symptoms suggestive of temporal arteritis. Cigarette smoking has been 
described significantly more common among these patients than in the general population. 
In patients with no obvious systemic risk factors and especially in subjects under the age of 
40, the other causative options should be considered, which include systemic vasculitis, 
blood dyscrasias, drug abuse, hypercoagulabile states, infective diseases, migraine and 
prolonged direct pressure to the globe in unconscious patients (Brown et al., 1981; Graham, 
1990; Greven et al., 1995).  
Coagulopathies from sickle cell anemia or antiphospholipid antibodies are more common 
etiologies for CRAO in patients younger than 30 years of age and the proposed mechanisms 
involve increase in coagulation factor or platelet activity, thrombocytosis, interaction of lupus 
anticoagulant and anticardiolipin antibodies with phospholipids as well as the deficiencies of 
protein C and S and resistance to activated protein C (Comp & Esmon, 1984; Love & Santoro, 
1990; Palmowski-Wolfe et al., 2007; Vignes et al., 1996). Increased levels of homocysteine have 
been linked with higher incidence of occlusive vascular incidents damaging the vascular 
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endothelium and thus increasing atherosclerotic changes and the formation of blood cloths. 
Therefore, in cases of suspected homocystinuria or heterozygosity for homocystinuria an oral 
methionine loading test may be performed since this state may be preventable by taking 
appropriate vitamin supplements (Boers et al., 1985; Weger et al., 2002; Wenzler et al., 1993). In 
cases of clinical suspicion, the HIV testing may be indicated since there have been case reports 
of CRAO or BRAO associated with HIV infection (Conway et al., 1995). A variety of other 
diseases, including systemic lupus erythematosus, polyarteritis nodosa, dengue fever, West 
Nile virus, sickle cell disease, Takayasu’s arteritis, after smallpox vaccination, Churg-Strauss 
syndrome, ocular Behçet’s disease, Fabry’s disease, Susac'c syndrome, and head injury may 
present with retinal occlusive disorders. It is necessary to exclude these states if there is a 
young person with sudden loss of vision, fundoscopic findings of arterial occlusion, central or 
branch, and no obvious identifiable systemic risk factors as above mentioned. In conclusion, 
arterial occlusive disease of the retina is the result of either arteriosclerotic thrombosis, embolic 
impaction (predominantly atheromatous plaques of carotid bifurcation, or the internal carotid 
artery, but also consisting of different material – fat, parasites, talc, air), vasculitis, vasospasm 
or systemic hypotension. These numerous potential causes mandate often time-consuming 
and expensive lab tests, and sometimes a causative management of the underlying disease. 
The possible causes and underlying states associated with retinal arterial occlusion are 
incorporated in Table 1.  
2.4 Clinical presentation 
2.4.1 Symptoms 
The main presenting symptom of the arterial occlusive disease is loss of vision, usually 
monocular, which may be sudden (seconds to minutes) blurring, decrease or total loss of 
vision. The extent of visual loss depends on the type of the occlusion. In central artery 
occlusions, visual loss is central and dense. In branch artery occlusions, visual loss may go 
unnoticed if only a section of the peripheral visual field space is affected. Various types of 
the retinal artery occlusion have different degree of visual acuity (VA) drop; CRAO 
characterizes severely decreased VA (counting fingers to light perception); BRAO has VA 
20/20 to counting fingers; VA in cilioretinal occlusion ranges from 20/30-20/60; CRAO with 
cilioretinal sparing has VA 20/30 to hand motion, depending on the amount of the 
papillomacular bundle supplied by the patent vessel; combined CRAO and CRVO have VA 
counting fingers to light perception (Rumelt S, Brown GC, 2004). The patients with CRAO 
without cilioretinal sparing rarely regained any useful vision (Brown & Shields, 1979). 
Pain accompanying the visual loss is unusual and usually denotes associated ocular 
ischemic syndrome (Werner et al. 1994). Rarely, in cases associated with arterial spasm, a 
relapsing and remitting course of visual loss precedes central retinal artery obstruction. 
Amaurosis fugax precedes visual loss in about 10% of patients involving transient loss of 
vision lasting seconds to minutes, but which may last up to 2 hours (Brown, 1999). The 
vision usually returns to baseline after an episode of amaurosis fugax. 
2.4.2 Signs 
In CRAO, the first signs are afferent pupillary defect on the affected side and segmental 
arterial blood flow (“box- carring”), which appear immediately at the occlusion and are 
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accompanied by the various degree of diminished visual acuity. Later signs are retinal 
opacification and cherry-red spot and optic disc pallor, attenuation of the retinal arteries, 
arterio-arteriolar collaterals or neovascular glaucoma (as a complication). Von Graefe was 
the first one who described typical fundoscopic findings associated with occlusion of the 
central retinal artery: whitish, edematous retina attributable to infarction, especially at the 
posterior pole where the nerve fibre layer and ganglion cell layer are the thickest (Beatty & 
Au Eong, 2000). As these layers are absent in the fovea, the underlying choroidal vascular 
bed can be seen in this area, thus giving rise to the classic cherry-red spot (Fig. 1.). In the 
presence of a patent cilioretinal artery, the retinal region served by the unobstructed vessel 
is not involved (Fig. 2.). Disc pallor and retinal vascular narrowing are characteristic of the 
late stage of CRAO. The characteristic of BRAO is retinal edema in the distribution of the 
affected vessel only (Fig. 3.). Obstruction of a cilioretinal artery, or even a macular branch 
arteriole, gives cloudy, edematous appearance of the macula and affects central vision. In 
acute stage, the arteries appear thin and attenuated while cherry red spot and ground glass 
appearance may take hours to develop. In severe blockages, both veins and arteries may 
manifest “box-carring” or segmentation of the blood flow. 
 
Fig. 1. Central retinal artery occlusion, note foveal cherry red spot and ground glass 
appearance of the macula (arrow) 
 
Fig. 2. Cilioretinal sparing central artery occlusion; sparing between the disc and fovea 
(arrows), representing irrigation area of the cilioretinal artery  
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Fig. 3. Branch retinal artery occlusion; note pale, edematous retina in the area of affected 
vessel (arrows) 
Late complication of CRAO is a neovascularization which indicates severe retinal ischemia 
and is more common at the far periphery and not at the optic disc or the posterior pole, and 
may complicate with vitreous or preretinal hemorrhage (Duker & Brown, 1989). This is why, 
in most cases, they are not observed clinically or angiographically with standard angle 
fundus camera. Only ischemia is usually seen by fluorescein angiography. The typical 
angiographic finding of neovascularization is the leakage of dye, whereas collateral 
shunting vessels do not present with such a feature. The fundoscopic findings typically 
resolve within days to weeks of the acute event, and residual optic atrophy may be the only 
physical finding. This feature also explains why it is crucial to treat the far periphery of the 
retina by cryo in addition to treatment by photocoagulation, in cases that the retinal 
periphery cannot be treated by photocoagulation. 
Acute simultaneous obstruction of both the retinal and choroidal circulations is referred to 
as an ophthalmic artery obstruction. It can be differentiated clinically from central retinal 
artery obstruction by the following features: severe visual loss—bare or no light perception; 
intense ischemic retinal whitening that extends beyond the macular area; little to no cherry-
red spot; pronounced choroidal perfusion defects on fluorescein angiography; 
nonrecordable electroretinogram; and late retinal pigment epithelium alterations (Brown et 
al., 1986). Cases of ophthalmic artery obstruction usually have associated local orbital or 
systemic diseases: orbital mucormycosis, orbital trauma, retrobulbar anesthesia, depot 
corticosteroid injection, atrial myxoma, or carotid artery disease (Sullivan et al., 1983). In 
conjunction with ipsilateral ischemic optic neuropathy, temporal arteritis may produce 
ophthalmic artery obstruction. 
2.5 Evaluation and imaging 
To summarize and to choose a rational approach in the workup, it is our opinion that the 
evaluation should be related to the age group. We recommend the following procedures to 
be undertaken in the persons over 50 years: the physical examination with complete 
cardiovascular assessment, ECG, the lab tests including full blood count, erythrocyte 
sedimentation rate, C reactive protein, fasting blood glucose, lipidogram, urine analysis, 
Doppler color imaging of the carotid arteries, and transthoracic echocardiography in 
patients with cardioembolic risk factors.  
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In the younger patients and those with unidentifiable systemic risk factors these are the 
proposed investigations: fluorescein angiography, vasculitis screen including anticardiolipin 
antibodies, antinuclear antibodies, anti-double stranded DNA antibodies, routine 
coagulation tests (prothrombin time, partial thromboplastin time), specialized clotting factor 
and platelet activity studies (levels of protein S, protein C, antithrombin III, plasminogen 
activator, plasminogen activator inhibitor, fibrinogen and resistance to activated protein C) 
and homocysteine.  
 
Systemic cardiovascular disease 
 Hypertension, Diabetes mellitus, Atheromatous disease, Cardiac-valvular 
 disease, bacterial endocarditis, myxoma, arrhythmias  
Coagulopathies 
 Antiphospholipid antibodies, Protein C deficiency, Protein S deficiency, 
 Antithrombin III deficiency, Elevation of platelet factor 4, Sickle cell anemia, 
 Homocysteine 
Systemic vasculitis 
 Polyarteritis nodosa, Temporal arteritis, Kawasaki's syndrome, Wegener's 
 granulomatosis, Susac's disease, Systemic lupus erythematosus 
Oncologic 
 Metastatic tumors, Leukemia, Lymphoma  
Infective diseases 
 Syphilis, HIV  
Trauma 
 Direct ocular compression, Penetrating injury, Retrobulbar injection, Orbital 
 trauma, Purtscher's disease 
Ocular conditions 
 Preretinal arterial loops, Optic nerve drusen, Necrotizing herpetic retinitis, 
 Toxoplasmosis 
Other causes 
 Oral contraceptives, Pregnancy, Drug abuse, Migraine 
Table 1. Systemic and ocular conditions related to retinal arterial occlusion 
It is important to exclude temporal arteritis in older patients, since it follows different 
clinical course and mandates the prompt administration of systemic corticosteroids. Giant 
cell arteritis is concerned as approved clinically if two of the three symptoms or signs exist: 
headache, tenderness over the temple and high sedimentation rate. Biopsy only approves it 
and treatment should not be deferred for biopsy result. It should be immediately initiated if 
two or more of the above are present. The purpose of the treatment is to prevent visual loss 
of the fellow eye, which usually occurs within 10 days of the event in one eye. Apart from 
the sudden, painless, nonprogressive vision loss in one eye, the patients may have 
headaches, jaw claudication, scalp tenderness, proximal muscle and joint aches, anorexia, 
weight loss, or fever. 
All patients with acute retinal arterial occlusion must be evaluated for the source of 
embolism, which is the commonest cause for its development. The imaging techniques are 
used to confirm the diagnosis in uncertain cases and these are fluorescein angiography, 
visual field testing, optical coherence tomography and electroretinography.  
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2.5.1 Fluorescein angiography 
Fluorescein angiography is not routinely indicated in the acute phase of arterial occlusive 
disease. The angiographic findings in both types, CRAO and BRAO (Fig. 4.), include 
delayed arm-to-retina time which is over 12 seconds (Richard G. et al., 1998), reduced 
arterial caliber and “cattle-trucking” of the blood column in the branch arteries. Sometimes, 
it may be minutes before the retinal arterial tree fills with fluorescein. Arteriovenous transit 
is also delayed, and late staining of the disc is common. 
The CLRA dyes concurrently with the filling of the choroid and usually before the start of 
filling of the CRA (Justice & Lehmann, 1976). 
 
 
 
Fig. 4. Superior branch retinal artery occlusion of the right eye. Note the delayed filling of 
the dye in the superior quadrant of retina 
2.5.2 Visual field testing 
Visual fields show a remaining temporal island of peripheral vision. In cases of a patent 
cilioretinal artery, a small intact central island is found as well. 
2.5.3 Electroretinography 
Electroretinography characteristically shows a decreased to absent b-wave with intact a-
wave.  
2.5.4 Optical Coherence Tomography (OCT) 
Optical coherence findings depend on the duration of the ischemia. Acute stages show 
increased reflectivity in the inner retinal layers and decreased reflectivity of the 
photoreceptor layer due to the shadowing effect (Fig. 4.). If involved, the macular region 
shows cystoid changes with loss of the foveolar contour. Old cases of arterial occlusion are 
presented with macular thinning with increased reflectivity of the retinal structure denoting 
ischemia. 
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Fig. 5. CRAO – OCT changes, retinal edema in the inner layers (white arrows) denoting 
ischemia and the shadowing effect in the photoreceptor layer (black arrows) 
2.5.5 Color Doppler imaging 
Color Doppler imaging is an ultrasonographic evaluation of the blood flow characteristics of 
the retrobulbar circulation. Color Doppler studies of acute central retinal artery obstruction 
show diminished to absent blood flow velocity in the central retinal artery, generally with 
intact flow in the ophthalmic and choroidal branches (Sharma, 1998). Color Doppler 
imaging can be used to detect calcific emboli at the lamina cribrosa and also may be used to 
monitor blood flow changes induced by therapy. In addition, carotid artery studies may be 
carried out concurrently with ocular blood flow determinations to evaluate the possible 
causes of the central retinal artery obstruction. It is, however, important to determine the 
presence of plaques in the inspected vessels that are often the source of microemboli 
responsible for the occlusive event. In doubtful cases, the above-mentioned physical 
examination and laboratory testing should be carried out, especially in subjects younger 
than 40 years of age (Table 2). 
2.6 Differential diagnosis 
Ocular ischemic syndrome 
Purtscher’s retinopathy 
Severe commotio retinae 
Inflammatory or infectious retinitis 
2.7 Management 
Due to the poor prognosis of retinal artery occlusions, several treatment approaches have 
been attempted. These can be divided into two major categories: (1) conservative treatment, 
including mechanical (ocular massage and paracentesis), pharmacologic, and other means; 
and (2) invasive treatment, including catheterization of the proximal ophthalmic artery, 
usually through the femoral artery with infusion of thrombolytic agents. Any treatment that 
results in a statistically higher percentage of visual recovery compared with the spontaneous 
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recovery rate and has a low risk for morbidity and mortality could be considered the 
treatment of choice (Rumelt & Brown, 2003). 
2.7.1 Management of central retinal artery occlusion 
Conservative treatment 
 First step is arterial vasodilatation using sublingval isosorbid dinitrat, or CO2 
rebreathing in the bag; 
 Reduction of intraocular pressure (IOP) and improvement of perfusion by means of 
antiglaucomatous treatment topically (timolol, etc), systemically (manitol), or surgically 
by paracenthesis; 
 Ocular massage to move embolus further downstream through artery circulation in 
distant arterioles. Begin ocular massage with 3-mirror contact lens. Press the lens 
repeatedly for 10 seconds until the appearance of pulsation; or in the absence of 
pulsation, until collapse of the retinal blood flow. Observation for improvement of 
retinal blood flow is made through the lens during the ocular massage. If blood 
supply improves, ocular massage can be stopped and no further steps are required. 
If the blood flow does not improve, ocular massage should be continued 
meticulously for approximately 20 minutes. In addition, treatment prior to 24 hours 
is more highly to be successful and the success depends on the type of the embolus 
(calcified are the resistant ones). No light perception is also indication to start 
treatment. Our experience supports the statement  of others that even patients with 
no light perception may recover (this was also seen in cases of orbital compartment 
syndrome) (Rumelt et al, 1999); 
 During the ocular massage, administer acetazolamide 500 mg IV; 
 During the ocular massage, administer mannitol 20% 1 mg/kg IV or glycerol  
1ml/kg PO; 
 Scleral paracenthesis or anterior chamber paracenthesis – anesthetize the limbus 
with q-tip soaked with lidocaine 4%, and perform anterior chamber paracentesis 
with 25-G needle withdrawing  0.2 ml of aqueous humor; 
 Antiplatelet therapy (streptokinase 750 000 I.U. IV, urokinase), heparin therapy, 
isovolemic haemodilution, which basically make no sense if there is no circulation in 
the occluded artery and agents cannot reach the embolus (Hayreh, 2011); 
 Pentoxyfilline injection intravenously to reduce red blood cell rigidity; 
 Systemic steroids, in case where CRAO is caused by giant cell arteritis; 
 yperbaric oxygenation is one of the promising ways of treatment (Weinberger et al., 
2002; Bradvica et al., 2009), which can override the time to artery recanalization. 
However, there is still need for further evaluation because of the lack of greater 
randomized studies. 
Invasive treatment 
 Nd:Yag laser arteriotomy and embolectomy (Opremcak et al., 2008), although this 
rather invasive treatment frequently caused vitreous hemorrhage and need for 
vitrectomy, so it requires further evaluation; 
 Local intraarterial trombolysis, one of the very enthusiastically announced approaches 
in CRAO therapy, which is suspended due to a high adverse reactions incidence as 
www.intechopen.com
 Retinal Vascular Occlusions 
 
369 
reported by the last European Assessment Group for Lysis in the Eye Study (EAGLE) 
(Schumacher et al., 2010). Probable reason for the high complication rate was the 
inexperience of some of the participating physicians. The results and complications 
were much lower when the procedure was performed by one group (Schmidt et al., 
1992; Schumacher et al., 1993). 
Since the outcome of invasive treatment depends on the experience of the physician and 
therefore is not applicable to most centers, the best treatment so far is the conservative 
multi-step treatment that requires the persistence of the physician (Rumelt et al, 1999). 
2.7.2 Management of branch retinal artery occlusion 
Management of BRAO depends on the type of occlusion; either it is permanent or transient. 
In permanent BRAO, like in CRAO there are a lot of advocated treatments but none of them 
has proven efficient. Transient BRAO does not require any treatment at all except a 
thorough diagnostics to establish the cause of the occlusion and possibly prevent permanent 
BRAO from occurring. Nonarteritic cilioretinal artery occlusion (CLRAO) can be treated 
with any of the procedures described in CRAO treatment. Only arteritic CLRAO associated 
with giant cell arteritis (GCA) has to be treated with a high dose of steroids, i.e. treat GCA to 
prevent affecting the other eye and total blindness. 
It is important that CRAO and BRAO are both emergencies and any procedures leading to 
recanalization, or improving the outflow, have to be done urgently inside 97 min from the 
onset of occlusion (Hayreh et al., 2004), and certainly not after 240 min, because after that 
time the most part of the retinal tissue function is probably destroyed. It has to be 
emphasized though that these results are valid for experimental models in primates and for 
complete occlusion and not for humans that usually have partial obstruction. That is 
probably the reason why the treatment may be successful even more than 24 hours after the 
occlusion and the onset of symptoms. Therefore, prevention and education of patients to 
present immediately to an ophthalmologist or emergency care unit may be the one of the 
measures of improving the chances of treatment in such patients. 
3. Retinal Vein Occlusion 
Retinal vein occlusion (RVO) has been recognized as an entity since 1855 (Liebreich, 1855) 
and is one of the most common causes of acquired retinal vascular abnormality in adults as 
well as the frequent cause of visual loss. However, the pathogenesis and management of this 
disorder remains somewhat of an enigma. Current treatments for RVO and its sequelae are 
still evolving. 
CRVO and HCRVO are commonly subdivided into nonischemic and ischemic (hemorrhagic) 
types according to the degree of obstruction. Ischemic type occurs in more severe (complete) 
obstruction. Such a distinction is relevant to the clinician, since these two types have very 
different clinical features, visual outcomes, complications, prognosis and management. 
Nonischemic RVO is a comparatively benign disease, with central scotoma, essentially due to 
macular edema, as its major complication, with no risk of ocular neovascularization. Ischemic 
RVO, by contrast, is a seriously blinding disease, since up to two thirds of patients develop the 
devastating complications of ischemia, and neovascularization that lead to neovascular 
glaucoma which causes blindness (Hayreh, 1994). 
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Retinal vein obstruction is divided into central (CRVO), an occlusion of the central retinal 
vein resulting in four quadrants of retinal involvement; hemi-central retinal vein occlusion 
(HCRVO) and branch (BRVO) which consists of major BRVO, an occlusion of either a major 
branch retinal vein draining one quadrant of the retina, macular BRVO (Hayreh, 1994), an 
occlusion of a macular branch vein draining a portion of the macula, and peripheral BRVO, 
an occlusion of a branch retinal vein draining a portion of the retinal periphery. According 
to the most study data, hemicentral (HCRVO) is an anatomic variant of central retinal vein 
occlusion (CRVO). Thus, HCRVO acts more like CRVO in terms of risk factors, visual 
outcome, risk of neovascularization, and response to laser treatment (Appiah & Trempe, 
1989). CRVO and BRVO have both differences and similarities in pathophysiology, 
underlying systemic associations, average age of onset, clinical presentation, prognosis 
(natural history, complication rate) and treatment. 
Furthermore, central and hemi-central occlusion are divided into ischemic and nonischemic 
subtypes each having different clinical implications and ischemic carrying the risk of 
developing macular edema and devastating consequences regarding the visual function.  
3.1 Epidemiology 
The worldwide RVO prevalence, according to the meta-analysis which used pooled data 
from 15 different international studies involving over than 50,000 participants, ranged from 
30 to 101 years, has been calculated per 1000 as follows: 5.20 for any RVO, 4.42 for BRVO, 
and 0.80 for CRVO. On the basis of these rates, projected to the world population, 16.4 
million adults are affected by RVO (Rogers et al., 2010). For comparison, more than 171 
million adults with diabetes worldwide either have diabetic retinopathy or are at risk of 
developing this potentially blinding disease, according to a 2005 World Health Organization 
report (Wild et al., 2004). An estimated 13.9 million people globally are affected by BRVO 
and 2.5 million by CRVO. Prevalence varied by race/ethnicity and increased with age, but 
did not have a sex predilection. The age- and sex-standardized prevalence of any RVO was 
3.7 per 1000 in whites, 3.9 per 1000 in blacks, 5.7 per 1000 in Asians, and 6.9 per 1000 in 
Hispanics. Prevalence of CRVO was lower than BRVO in all ethnic populations. Although 
BRVO prevalence appears to be highest in Asians and Hispanics and lowest in whites, the 
authors assume this may reflect differences in the prevalence of RVO risk factors, varying 
methodologies or definitions among reviewed studies (Rogers et al., 2010). Ischemic central 
retinal vein obstructions account for 20–25% of all central retinal vein obstructions (Klein et 
al., 2000). 
3.2 Pathophysiology 
All types of RVO are multifactorial in origin. A whole host of local and systemic factors 
acting in different combinations and to different extent may produce the vascular occlusion. 
The role of the various factors may vary, with some as predisposing factors and other as 
precipitating ones in one group and vice versa in another. Most investigators accept that 
BRVO and CRVO represent varying degrees of the same underlying disease process. Yet, 
other clinicians and researchers argue that ischemic and nonischemic types are distinct 
clinical entities. It is also essential to understand that CRVO and HCRVO are very different 
from BRVO pathogenetically. In conclusion, it is a mistake to try to explain all types of RVO 
by one common pathogenetic mechanism (Hayreh, 1994). 
www.intechopen.com
 Retinal Vascular Occlusions 
 
371 
3.2.1 Central Retinal Vein Occlusion 
The pathogenesis of CRVO is not fully understood and there are marked controversies on 
the pathogenesis of ischemic and especially nonischemic CRVO. A combination of vascular, 
anatomic, and inflammatory factors contributes to its pathophysiology.  
The occlusive mechanisms in CRVO are mostly these: (i) external mechanical compression 
of the vein (i.e. by sclerotic adjacent central retinal artery and common adventitia, especially 
in elderly persons, structural changes in lamina cribrosa, e.g., glaucomatous cupping, 
inflammatory swelling in optic nerve and orbital disorders) followed by secondary 
endothelial proliferation; (ii) primary venous wall disease (degenerative or inflammatory); 
and (iii) hemodynamic disturbances produced by a variety of factors (e.g., hyperdynamic or 
sluggish circulation, blood dyscrasias, disturbances on the arterial side, etc.). Consequently, 
a stagnation of the vein flow occurs and a thrombus formation ensues (Hayreh, 1994; 
Williamson, 1997). 
There are multiple anatomic variations of the branching pattern to the central retinal vein. In 
20% of eyes there are, as a congenital abnormality, two trunks of the central retinal vein 
(CRV) in the optic nerve (instead of the usual one), and the merging of the trunks occurs 
posterior to the lamina cribrosa (Chopdar, 1984; S. S. Hayreh & M. S. Hayreh, 1980). If one of 
these trunks is occluded, the result is a nonperfusion to superior or inferior retina. 
Additionally, the venous outflow from the nasal retina may occur via a branch of one of the 
temporal branches, rather than an independent nasal vein. In an eye with such a branching 
pattern, an inferior or superior HCRVO may occur if one the venous branches that drain the 
nasal and temporal retina is occluded (Sanborn & Magargal, 1984). So, considering the 
various possible scenarios that can result in a HCRVO, a consensus as to whether HCRVO is 
a variant of BRVO or CRVO still has not been reached. 
CRVO is significantly more common in patients with raised intraocular pressure (IOP) and 
glaucoma (up to 5- to 10-fold increased risk) (Risk factors for central retinal vein occlusion. 
The Eye Disease Case-Control Study Group, 1996). To maintain the blood flow, the pressure 
in the CRV at the optic disc has to be higher than the IOP, otherwise a retinal venous stasis 
and sluggish venous outflow occur (Hayreh, 2005). 
There is much more congruence of the data on the pathogenesis of the ischemic CRVO. Most 
probably ischemic CRVO represents a more extensive (or complete) obstruction while non-
ischemic RCVO represents a milder (partial) obstruction. A conception suggests that the 
vessels are in a tight compartment within limited space for displacement, because of a 
common adventitial sheath as CRA and CRV exit the optic nerve head and pass through a 
narrow opening in the lamina cribrosa. This anatomical position per se predisposes to 
thrombus formation in the central retinal vein. But, CRV has multiple tributaries during its 
course in the optic nerve, pial outside the optic nerve, none in the lamina cribrosa, and only 
a small one in the prelaminar region. These tributaries establish anastomoses with the 
surrounding veins. Since the severity of retinal venous stasis depends upon the site of 
occlusion in the CRV, and the number of available tributaries anterior to it, the site of the 
occlusion is likely to be much posteriorly to the lamina cribrosa in nonischemic CRVO than 
in ischemic CRVO (Hayreh, 2005). There is a possibility of changing nonischemic CRVO to 
ischemic in some patients, probably due to a further precipitous gradual or sudden fall of 
perfusion pressure (Hayreh, 1994). 
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Occlusion of the central retinal vein leads to the retention of the blood in the retinal venous 
system, and increased resistance to venous blood flow subsequently causes a stagnation of 
the blood and ischemic damage to the retina. It has been postulated that ischemic damage to 
the retina stimulates increased production of vascular endothelial growth factor (VEGF) in 
the vitreous cavity. Increased levels of VEGF stimulate neovascularization of the posterior 
and anterior segment (responsible for secondary complications due to CRVO). Also, it has 
been shown that VEGF causes capillary leakage leading to macular edema (which is the 
leading cause of visual loss in both ischemic CRVO and nonischemic CRVO) (Boyd et al., 
2002; Noma et al., 2008; Pe'er et al., 1998). 
The prognosis of CRVO depends upon the reestablishment of patency of the venous system 
by recanalization, dissolution of clot, or formation of optociliary shunt vessels. 
3.2.2 Combined Retinal Vein and Artery Occlusion 
A central retinal artery obstruction combined with central retinal vein obstruction can occur 
rarely (Richards, 1979), and the mechanism is probably increased pressure on both central 
retinal artery and vein. The most common cause for combined CRAO and CRVO is 
retrobulbar anesthetic injection, caused probably by inadvertent injection into the optic 
nerve sheath (Torres, 2005). If no CRV tributaries are available anterior to the site of 
occlusion in the CRVO, it converts the circulation into a closed loop and this results in 
complete hemodynamic block of the retinal circulation, and secondary CRAO. This 
condition is invariably diagnosed as simultaneous occlusion of CRA and CRV (Hayreh, 
2005). Nonischemic CRVO associated with cilioretinal artery occlusion (CLRAO) is usually a 
result of transient rise i.e. a functional obstruction of the blood pressure in the entire retinal 
capillary bed due to a sudden blockage of blood flow by a thrombus in the CRV, which, in 
turn, results in a physiologic block in the CLRA circulation (Theoulakis et al., 2010). Within a 
day or two, with the development of venous collaterals by the CRV, the blood pressure in 
the retinal vascular bed falls, and normal cilioretinal filling occurs. However, the severity of 
retinal ischemia and associated visual loss depends upon the length of time elapsed before 
the circulation was re-established (Hayreh, 1994). 
3.2.3 Branch Retinal Vein Occlusion 
Branch retinal vein occlusion is defined as a focal occlusion of a retinal vein at an arterio-
venous crossing site. In all but a few rare cases, the BRVO occurs at crossing sites where the 
artery is passing anteriorly (superficially) to the vein (Duker & Brown, 1989; Weinberg et al., 
1990). The upper temporal vascular arcade is more often involved than the lower temporal 
vascular arcade. Most BRVOs involve the area inside the temporal vascular arcades 
(macular BRVO), whereas peripheral BRVOs are more rarely seen, partly because they tend 
to be asymptomatic (Christoffersen & Larsen, 1999). 
The arterio-venous crossing plays an important role in the pathogenesis of BRVO, and the 
anterior position of the arteriole at the crossing somehow renders the underlying vein 
vulnerable to occlusion. It seems logical to assume that sclerotic retinal arteriole probably 
compresses the accompanying vein because of a common thickened, adventitial and glial 
sheath; however, histopathological studies failed to confirm this view. In addition, turbulent 
flow may injure the vessel wall exposing it for thrombus formation (Hayreh, 1994; 
Williamson, 1997). 
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3.3 Causes 
Retinal vascular occlusions all have overlapping clinical presentation as well as the similar 
underlying causes. They are all multifactorial in origin and each patient may have a unique 
combination of systemic and local factors leading to the occlusive event (Hayreh, 1994). 
Since the systemic vascular disease is a possible underlying pathophysiological cause, it is 
important to ask about history of hypertension, diabetes mellitus, any condition 
predisposing embolic events (endocarditis, atrial fibrillation, atherosclerotic disease, drug 
and alcohol abuse, hypercoagulabile states) (Klein et al., 2003; Schmidt et al., 2007). Also, the 
questions regarding possible trauma as well as the undertaken surgical procedures should 
not be omitted from the medical history since the prolonged pressure to the globe may lead 
to the ischemic event.  
The well-known risk factors contributing to retinal vein occlusions are systemic vascular 
diseases. The most recognized risk factors for retinal vein occlusion are hypertension, 
diabetes mellitus, arteriosclerosis and hyperlipidemia. Also, cigarette smoking has been 
related to increased risk of RVO. They predominately affect the older age group of patients 
but the younger patients may also develop this type of retinal occlusive disorder and they 
account for 10-15% of patients with RVO. Mild central retinal vein obstructions in patients 
younger than 50 years have been referred to as papillophlebitis or optic disc vasculitis. An 
inflammatory optic neuritis or vasculitis is hypothesized as the cause (Fong, 1992).  
According to the recent studies by Hayreh et al. there may be some difference in the risk 
factors between CRVO and BRVO, with higher prevalence of hypertension, venous disease, 
peripheral vascular disease and peptic ulcer in the latter (Hayreh et al., 2001). This suggests 
that it may not be correct to generalize about these underlying causes for the entire group of 
retinal vein occlusions.  
In addition to well-recognized risk factors, new thrombophilic factors have been 
investigated in these patients. The role of thrombophilic risk factors in RVO is controversial 
and the studies are showing conflicting results. Hyperhomocysteinemia as well as low levels 
of vitamin B6 and folic acid have been identified as independent risk factors (Sofi et al., 2008; 
Taubert, 2008). Other potential risk factors include elevated factor V Leiden, protein C or S 
deficiency, anti-cardiolipin antibodies or lupus anticoagulant. Blood dyscrasias and 
dysproteinemias result in hyperviscosity syndromes, which may appear similar to central 
retinal vein obstruction but possibly represent curable disease. Hyperviscosity syndromes 
may produce a bilateral retinopathy similar to central retinal vein obstruction and may, in 
fact, induce a true central retinal vein obstruction with thrombus formation (Bandello et al., 
1994). Simultaneous bilateral disease is an unusual finding in central retinal vein 
obstructions but occurs more commonly in hypercoagulabile and hyperviscous states. 
Diseases such as sickle cell disease, polycythemia vera, leukemia, and multiple myeloma are 
but a few of the possibilities. When there is a patient with bilateral central retinal vein 
obstructions, especially simultaneous, the medical and laboratory evaluation should include 
a search for evidence of hyperviscous and hypercoagulabile syndromes (Marcucci et al., 
2001) Severe anemia with thrombocytopenia can masquerade as a central retinal vein 
obstruction, and it is differentiated from a central retinal vein obstruction by a complete 
blood count with platelets. 
In combined central retinal vein occlusion with branch retinal artery occlusion systemic 
associations other than hypertension and diabetes have not been confirmed. In combination 
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with central retinal artery occlusion associated systemic or local disease is the rule—collagen 
vascular disorders, leukemia, orbital trauma, retrobulbar injections, and mucormycosis have 
been implicated (Jorizzo, 1987). 
Oral contraceptive use in women may be associated with both thromboembolic disease and 
central retinal vein obstruction (Stowe et al., 1978). In addition, acute hypertensive 
retinopathy with disc edema may resemble bilateral central retinal vein obstruction. 
Obstructive sleep apnea affects more patients with retinal vein obstruction than other 
disorders and treatment of the sleep apnea may help prevent central vein obstruction 
(Glacet-Bernard et al., 2010). Other rare associations include closed-head trauma, optic disc 
drusen, and arteriovenous malformations of retina.  
The Eye Disease Case-Control Study Group reported that the risk of CRVO is decreased in 
men with increased levels of physical activity and increased alcohol consumption (Risk 
factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group, 1996). 
The same study group reported a decreased risk of CRVO with the use of postmenopausal 
estrogens and an increased risk with higher erythrocyte sedimentation rates in women. 
An ocular risk factor for the development of central retinal vein occlusion is raised 
intraocular pressure; the risk of central retinal vein occlusion in glaucoma patients is 5-fold 
to 10-fold increase (Risk factors for central retinal vein occlusion. The Eye Disease Case-
Control Study Group, 1996). Unlike CRVO and HCRVO, glaucoma plays no role in the 
pathogenesis of BRVO (Hayreh, 1994). 
In ischemic CRVO, for example, neovascular glaucoma develops in about 45%. The chronic 
hypoxia of the retinal tissue induces ocular neovascularization by producing the 
vasoproliferative factor, which is the proposed mechanism in CRVO whereas in CRAO, 
there is acute retinal ischemia and infarction responsible for the occlusive event. Also a 
surprisingly small proportion of patients (2.5%) have the course of illness complicated with 
neovascular glaucoma (Hayreh, 2011). 
3.4 Clinical presentation 
3.4.1 Symptoms 
Retinal vein occlusion is characterized by painless unilateral loss of vision. It may be subtle 
in character, with intermittent episodes of blurred vision. In other cases, it may be sudden 
and dramatic. The nonischemic type is often the more subtle of the two, while the ischemic 
type is prone to the more acute clinical presentations and may be accompanied by pain. 
Ischemic CRVO Acute, markedly decreased visual acuity ranged from 20/200 (6/60) to 
hand-motion is the usual initial complaint. A prominent afferent pupillary defect is typical. 
Pain at the time of evaluation may occur if neovascular glaucoma already had developed. 
Nonischemic CRVO The majority of patients with central retinal vein obstruction (75–80%) 
fall into nonischemic form. Patients usually have mild to moderate decreased visual acuity, 
although this can vary from normal to as poor as the finger counting. Transient visual 
obscuration may also be a complaint. 
Branch retinal vein occlusion is characterized by painless decrease in vision on the affected 
eye and some patients may have a scotoma. 
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Combined Retinal Vein and Artery Occlusion Such patients present with acute, severe loss 
of vision, usually to bare or no light perception. The visual prognosis is generally poor. 
3.4.2 Signs 
The distinction between the ischemic and nonischemic type is important, because they carry 
a totally different prognosis regarding visual recovery and potential complication, which 
may result in permanent visual deterioration. 
Both types of central retinal vein obstruction, ischemic and nonischemic, have similar 
fundoscopic findings—dilated, tortuous retinal veins and retinal hemorrhages in all four 
quadrants, optic disc swelling, cotton wool spots and macular edema (Fig. 5). Hemorrhages can 
be superficial, dot and blot, and/or deep. They may vary in severity, covering the whole fundus 
and sometimes even obscuring retinal and choroidal details, or can be limited to the peripheral 
fundus only. Vitreous hemorrhage may ensue when bleeding breaks through the internal 
limiting membrane. The optic disc is usually edematous during the early-stage disease, but the 
edema may persist in chronic cases (Ehlers & Fekrat, 2011). Many or all of the pathological 
retinal findings may resolve over the 6–12 months following diagnosis. The resolution of retinal 
hemorrhages may be complete whereas the optic nerve may appear normal, but optociliary 
collateral vessels are common finding. In spite the resolution of macular edema, a persistent 
cystoid macular edema can linger and result in permanent visual loss, often leading to 
pigmentary changes, epiretinal membrane formation, or subretinal fibrosis.  
Ischemic CRVO The presence of cotton-wool spots located around the posterior pole is 
characteristic of and more common with ischemic CRVO (Fig. 6.). In ischemic CRVO, the 
ganglion cells in the macular retina are irreversibly damaged by ischemia during the initial 
stages of the disease; therefore, there is little chance of improvement of visual acuity in such 
an eye. The distinction between the two types of vein obstructions remains somewhat 
arbitrary and is based on the total area of nonperfusion on fluorescein angiography. 
However, dense intraretinal hemorrhage in acute stages may block retinal fluorescence and 
renders it impossible to determine the extent of retinal nonperfusion. Therefore, it is 
important to take into account other clinical features such as poor initial visual acuity, the 
presence of an afferent pupillary defect, neovascularization as well as the functional tests – 
visual field testing (Goldmann) and electroretinography (ERG) to establish the perfusion 
status of the retina (Hayreh et al., 2011). In central retinal vein obstruction, perfusion of the 
inner retina is affected, so that the amplitude of the b-wave is decreased relative to the a-
wave; the b-to-a ratio has been shown to be reduced. Some studies indicate that a b-to-a 
ratio of less than 1 suggests an ischemic central retinal vein obstruction (Matsui et al., 1994). 
It is only the ischemic CRVO eye which is at risk of developing ocular neovascularization 
(Hayreh et al., 1983; Natural history and clinical management of central retinal vein 
occlusion. The Central Vein Occlusion Study Group, 1997). The incidence of anterior 
segment neovascularization in ischemic central retinal vein obstruction is 60% or higher and 
has been documented as early as 9 weeks after onset of an occlusive event. The greatest risk 
of developing anterior segment neovascularization is during the first 7 months, after which 
the risk of dreaded complication of neovascular glaucoma falls dramatically to minimal. 
Neovascularization of the optic disc and retinal neovascularization may be seen as well, but 
they are less common. As with nonischemic central retinal vein obstruction, the findings 
may decrease or resolve 6–12 months after diagnosis. The anterior segment structures may 
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show signs of ischemia: congestion of the conjunctival and ciliary vessels, corneal edema, 
iris and anterior chamber angle neovascularization with development of synechial changes 
predisposing the development of secondary glaucoma.  
 
Fig. 6. Central retinal vein occlusion; dilated, tortuous retinal veins and retinal hemorrhages 
in all four quadrants, optic disc swelling (arrows), cotton wool spots and macular edema 
Nonischemic CRVO Neovascularization of either the anterior or posterior segment is rare in a 
true nonischemic central retinal vein obstruction (less than 2% incidence), although conversion 
from an initially nonischemic vein obstruction to the ischemic variety is fairly common. The 
Central Vein Occlusion Study Group noted that 34% of nonischemic central retinal vein 
occlusions (CRVOs) progressed to become ischemic within 3 years and 15% of the study group 
converted within the first 4 months (Natural history and clinical management of central retinal 
vein occlusion. The Central Vein Occlusion Study Group, 1997).  
Hemicentral RVO In hemicentral retinal vein obstruction venous outflow from the superior 
or inferior parts of retina is impaired. Although they involve half of the retina, in terms of 
visual outcome, the risk of neovascularization, and response to the laser treatment, they 
resemble the ischemic variant of the disease. 
Branch retinal vein occlusion (Fig. 7.) Intraretinal hemorrhages (usually flame shaped), 
retinal edema, and cotton-wool spots are seen in the distribution of a retinal vessel. 
Papillophlebitis The characteristic finding is optic disc edema out of proportion to the 
retinal findings, cotton-wool spots that ring the optic disc, and occasionally cilioretinal 
artery obstructions or even partial central retinal artery obstructions. Although spontaneous 
improvement occurs, the course is not always benign. Approximately 30% of these patients 
may develop the ischemic type of occlusion, a final visual acuity of 20/200 in nearly 40% of 
these subjects, and neovascular glaucoma has been reported (Fong, 1992). 
Combined Retinal Vein and Artery Occlusion Examination shows a cherry-red spot 
combined with features of a central retinal vein obstruction, which include dilated, tortuous 
veins that have retinal hemorrhages in all four quadrants (Fig. 8.). The risk of 
neovascularization of the iris is about 75%. Exceptionally, a patient may manifest 
spontaneous improvement (Jorizzo, 1987). Branch retinal artery obstruction combined with 
simultaneous central retinal vein obstruction has also been reported. This rare entity 
behaves as a central retinal vein obstruction. Neovascularization of the iris is possible. 
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Fig. 7. Branch retinal vein occlusion; note hemorrhages and edema in superior temporal 
quadrant (arrows) 
 
 
 
Fig. 8. Combined branch retinal artery occlusion (BRAO) and central retinal vein occlusion 
(CRVO) of the right eye, ischemia involving superior macular branches (arrows), optic disc 
swelling, tortuous veins and dot and blot hemorrhages 
3.5 Evaluation and imaging 
3.5.1 Systemic evaluation 
Given the heterogenity of risk factors and their possible interaction in these subjects, the 
following algorithm of patients with RVO is proposed in the Table 2. As for the arterial 
occlusive retinal disease, these tests should be performed in younger patients and in 
doubtful cases. 
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We feel that, as with the arterial occlusive disease, the stepwise approach to each patient 
should be tailored, taking into account the age of the patient. Therefore the investigations in 
the patients older than 50 years of age should consist of: cardiovascular risk assessment, 
ECG, carotid and vertebral artery Doppler color imaging, echocardiogram; the lab tests 
including full blood count, erythrocyte sedimentation rate, C reactive protein, fasting blood 
glucose, lipidogram. The younger patients should be evaluated for thrombophilia, 
hyperviscosity syndromes, screening for autoimmune diseases and women should be asked 
about the use of oral contraceptives. Of course, other possible causes of retinal vein 
occlusions should be considered in cases of normal findings and the investigations should 
be expanded in stepwise approach, since each case may have a unique combination of risk 
factors and underlying causes. 
 
  
 Cardiovascular risk factors assessment  
 (diabetes, hypertension, smoking  habitus, dyslipidemia, BMI)  
 ECG 
 Carotid and vertebral artery Doppler color imaging 
 Echocardiogram  
 (transthoracic, transesophageal in selected cases) 
 Lab tests  
 (complete blood count, fasting glucose, lipidogram, autoimmune screen in 
 selected cases: ANA, anti ENA, anti DNA; homocysteine level, folic acid, 
 vitamin B12 and B6, antiphospholipid antibodies) 
 Thrombophilia assessment in subjects younger than 50 years (factor V Leiden, 
 antithrombin, protein C, protein S) 
Table 2. Proposed systemic work-up in RVO patients 
Although most cases are diagnosed straightforward from the fundus appearance, the 
following ancillary tests may be undertaken to distinguish between ischemic or milder, 
nonischemic form, which is very important in terms of the treatment options as well as the 
natural course and visual prognosis of the patients.  
3.5.2 Fluorescein angiography 
Arteriolar filling is usually normal, but venous filling in the affected vessel is usually 
delayed in the acute phase. Hypofluorescence caused by hemorrhage and capillary 
nonperfusion are common findings, and dilated, tortuous veins are seen (Fig. 9a.). The 
retinal vessels, particularly the vein walls, may stain with fluorescein, especially at the site 
of the occlusion (Fig.10.). The very important distinction should be made between 
neovascular fronds, which may show profuse leakage of dye, vs. collateral vessels, which do 
not leak fluorescein. Cystoid macular edema (Fig. 9b.) appears in the late stage of the 
angoigram shows typically petaloid pattern and may involve the entire fovea or just several 
clock hours, depending on the distribution of the obstruction. It is, however, important to 
emphasize that in early stages the retinal angiograms may be misleading because of the 
masking by abundant hemorrhages and the fact that retinal capillary obliteration is a 
progressive phenomenon which takes at least 3-4 weeks or even longer to develop after the 
occurrence of ischemic CRVO (Hayreh, 1994). 
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Fig. 9. Fluorescein angiogram of the left eye with central retinal vein occlusion a and b. a) 
staining of blood vessel walls, disc hyperfluorescence and blockage from intraretinal 
hemorrhage b) the late stages of angiogram shows leakage of dye in cystoid macular edema, 
with characteristic “petaloid” appearance. 
   
Fig. 10. Fluorescein angiogram of the right eye with superior branch retinal vein occlusion a 
and b. a) blockage of dye with hemorrhages, mottled areas of intraretinal leakage and 
microaneurysm formation with vascular teleangiectasia in the upper parts b) the late stages 
of angiogram shows further diffuse leakage of dye, through all layers of the retina, affecting 
the macular region as well. 
3.5.3 Optical coherence tomography 
The optical coherence tomograms show increase in the retinal thickness, which is seen as a 
loss of macular contour. In the area of edematous retina the presence of cystoids spaces 
denotes the existence of cystoid macular edema (Fig. 11.). The retinal hemorrhages, 
subretinal fluid accumulation, cotton wool spots and optic disc edema may also be 
visualized on OCT. OCT is useful in the management and treatment of the macular edema; 
it also offers certain advantages over angiograms because it quantifies the macular thickness 
useful in monitoring the response to treatment and gives valuable data on distribution of the 
fluid, is not invasive and has no potentially serious side effects. There have been some 
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disputes whether the macular thickness correlates significantly with visual acuity 
(Nussenblatt et al., 1987). What counts is the improvement in visual functions and not the 
anatomy. Several factors were predictive of better visual acuity outcomes and more 
favorable OCT outcomes, including younger age and shorter duration of macular edema, 
respectively. These factors may assist clinicians in predicting disease course for patients 
with CRVO and BRVO (Scott et al., 2011). Loss of foveal IS/OS junction line and absence of 
inner retinal layers in late stage significantly correlated with poorer visual outcome. 
Macular ischemia by fluorescein angiography shows significant correlation with thinner 
central subfield thickness, loss of inner retinal layers (Lima, 2011). 
 
  
Fig. 11 a and b. Optical coherence tomography (OCT) changes of eye with central retinal 
vein occlusion a) Cystoid macular edema prior to anti-VEGF injection; b) Cystoid macular 
edema after anti-VEGF injection treatment Cross-section goes through inferior retina to 
superior retina, capturing the abnormally thickened retina associated with intracellular 
edema. 
3.6 Differential diagnosis 
Hypertensive retinopathy 
Diabetic retinopathy 
Ocular ischemic syndrome 
Juxtafoveal retinal telangiectasia 
Radiation retinopathy 
Retinal artery occlusion 
Retinal detachment 
Vitreous hemorrhage 
3.7 Management 
Some treatments have addressed the venous outflow and the majority the sequelae of the 
venous occlusion (i.e. cystoid macular edema, neovascularization). In the following text the 
advocated treatment options are discussed. 
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3.7.1 Management of branch retinal vein occlusion 
Etiology treatment 
 Isovolemic hemodilution, used to lower plasma viscosity and to improve retinal 
perfusion. However, the true benefit of hemodilution has not been established because 
the published reports have used a combination therapy in the hemodilution groups ; 
 Laser chorioretinal venous anastomosis, performed to bypass the occluded site by 
inducing a communication between the involved branch vein and the choroidal 
circulation by placing a laser burn directly on the vein and then on the adjacent Bruch’s 
membrane. During the healing process, a chorioretinal anastomosis may form. The 
technique is studied on CRVO patient, but the small number of BRVO case series were 
reported (Bavbek et al., 2005; Fekrat et al., 1998); 
 Pars plana vitrectomy and arteriovenous sheathotomy. Arteriovenous sheathotomy, in 
which the retinal vein and artery are surgically separated at the arteriovenous crossing 
by cutting the common adventitial sheath bare the same idea of improving perfusion. 
Several small, uncontrolled series have shown good results in improving macular 
edema and macular perfusion. However, others have reported a lack of efficacy of this 
procedure (Le Rouic et al., 2001; Cahill et al., 2003). 
Sequelae treatment 
 Grid laser photocoagulation. The Branch Vein Occlusion Study (BVOS) demonstrated 
the efficacy of grid laser photocoagulation in the treatment of BRVO-related macular 
edema. According to the study, grid photocoagulation performed in the first 12 months 
of onset of the occlusion can, compared to the natural course, improved the response 
almost twice (Argon laser photocoagulation for macular edema in branch vein 
occlusion. The Branch Vein Occlusion Study Group, 1984) Argon laser grid or sector 
treatment result in resolution of the edema but do not improve visual acuity; 
 Sector Scatter Retinal Laser Photocoagulation. This treatment was also evaluated during 
the BVOS study in the ability of preventing the development of neovascularization and 
vitreous hemorrhage in the BRVO. It is recommended that scatter photocoagulation should 
be used in BRVO, if and when neovascularization occurs (Argon laser scatter 
photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch 
vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group, 1986); 
 Intravitreal corticosteroids, using a long lasting corticosteroid such as triamcinolone 
(IVTA), or biodegradable carrier containing dexamethasone to manage macular edema. 
SCORE study was conducted to compare IVTA versus standard of care, i.e. grid-pattern 
macular photocoagulation (Scott et al., 2009). The results of this study suggest that both 
procedures have a similar effect on resolving macular edema and improving visual acuity, 
but IVTA has more side effects (increasing IOP, cataract progression). In a randomized 
pilot study of subjects with cystoid macular edema (CME) secondary to BRVO, the 
increase in visual acuity was significantly greater in those treated with combination of 
IVTA and grid-pattern laser photocoagulation than in the eyes treated with grid-pattern 
laser alone, suggesting that IVTA can be effective as an adjunctive treatment to laser 
(Parodi et al., 2008). Allergan conducted an international study at 167 centers in 24 
countries on the effect of intravitreal dexamethasone sustained release delivery system 
(Ozurdex). The data for the first 6 months was released (Haller et al., 2010). It appears that 
visual acuity was significantly better in the group of patients who received 0.7 mg 
dexamethasone implant than in the control group after 60 and 90 days, but is similar 180 
days after the treatment. Ozurdex received FDA approval for treatment of macular edema 
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secondary to BRVO in 2009. An implantable fluocinolone acetonide (Retisert, Bausch and 
Lomb, Rochester, NY), at present being registered for the intravitreal treatment of chronic 
non-infectious uveitis, is also being evaluated for the treatment of BRVO and CRVO. The 
beneficial effect of intravitreal corticosteroids is limited in time and repeated treatment is 
associated with the accumulation of the complications including steroid-induced 
glaucoma, cataract, endophthalmitis and retinal detachment. IOP sparing corticosteroids 
may only prevent glaucoma but not the other side-effects; 
 Intravitreal Anti-Vascular Endothelial Growth Factor. It was noticed that VEGF plays a 
substantial role in the development of CME and neovascular complication in RVO 
patients. The first intravitreally used drug was bevacizumab, originally developed for 
the intravenous treatment of colorectal carcinoma metastases, but widely used for 
treating RVO complications and other retinal disorders (e.g. diabetic macular edema, 
age related macular degeneration). Several studies have reported a decrease in retinal 
thickness and improved visual acuity after receiving bevacizumab (Kreutzer et al., 2008; 
Kriechbaum et al., 2008; Pai et al., 2007). Visual acuity usually increased to maximum in 
3-6 weeks after the injections (Stahl et al., 2007). A subsequent decrease in visual acuity 
appeared to be closely related to an increase in CME. Early recurrence of CME should 
prompt consideration for retreatment. The most appropriate timing interval between 
injections is still unclear. The other anti-VEGF agents on the market are pegaptanib, the 
first FDA approved intravitreal agent (for the treatment of neovascular age-related 
macular degeneration - ARMD) and ranibizumab, the first FDA approved agent for the 
treatment of not only ARMD but also macular edema caused by BRVO, based on the 
results of BRAVO study. Results of phase III BRAVO study show us that after six 
monthly intravitreal injections of ranibizumab 55% (0.3mg group), and 61% (0.5mg 
group) gain more than 15 letters, compared to 28.8% in the control group. Also a central 
foveal thickness decreased by 158 microns in the control group versus 337 microns in 
the 0.3 mg group and by 345 microns in the 0.5 mg group. Adverse events are rare - one 
retinal detachment in the 0.3 mg group, one endophthalmitis and one myocardial 
infarction in 0.5 mg group, and one stroke in the control group. According to our 
experience as well as numerous other authorities it is doubtfull that myocardial 
infarction and stroke are caused by the local treatment with anti-VEGF, since they are 
most prominent in the older population which is prone to these conditions (Rosenfeld, 
2006). After six months the control group received intravitreal ranibizumab on as 
needed basis; i.e. if macular edema occurs. Therefore, the long-term results remain 
unknown. We can say that, according to this data, the use of anti-VEGF agents become 
an important option in macular edema treatment secondary to BRVO; 
 Pars plana vitrectomy with removal of the posterior hyaloid is effective in resolving 
CME (only if the traction is the cause of retinal edema and usually if the duration of the 
edema is less than 6 months) and improving visual acuity (Figueroa et al., 2004). Due to 
complications associated with these procedures, such as vitreous hemorrhage, 
intraoperative retinal tears, rhegmatogenous retinal detachment and cataract 
development, they are not often in use. 
3.7.2 Management of central retinal vein occlusion 
Etiology treatment 
 Isovolemic hemodilution. Several studies have suggested the presence of abnormal 
blood viscosity in CRVO patients. Based on that assumption, some authors have 
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advocated the use of hemodilution in CRVO, but other (Hayreh, 2003) claim that there 
is little scientifically valid evidence of beneficial effects of this therapy; 
 Anticoagulant and antiplatelet therapy. Although no clear ocular benefit of antithrombotic 
drugs has been demonstrated, antiplatelet drugs (e.g. aspirin) are prescribed for many 
patients, including CRVO patients. Hayreh (Hayreh, 2002) claims that this therapy as well 
as the anticoagulant therapy, such as recombinant tissue plasminogen activator (rt-PA), is 
contraindicated and even harmful for CRVO patients. Some authors have tried local 
application of rt-PA into retinal branch vein but the results are controversial and 
complication rate (haemophtalmus, neovascular glaucoma, retinal detachment, eye 
phthysis) is unacceptably high;  rt-PA should penetrate the retina to exert its activity  
 Chorioretinal venous anastomosis. The techniques explained earlier may create an 
anastomosis, but also carry significant risks. Given the variable success rate, these 
techniques are rarely employed; 
 Surgical decompression of the retinal vein. Proposed procedures can be divided into 
two mayor types; the first is the vitrectomy with radial optic neurotomy, in which a 
surgeon’s approach is from inside the globe, and the second is optic nerve sheet 
decompression using orbital “outer” approach. Because of the danger and invasiveness 
of the procedures and the lack of scientific explanation (Hayreh et al., 2002), there is a 
need for a larger study to eventually find a place for these procedures in the 
management of CRVO. 
Treatment directed at sequelae 
 When speaking of sequelae treatment, we have to add an antiglaucomatous treatment 
as needed if increase of IOP occurs. Local medical therapy such as, ǐ-blocker (timolol 
0,5%), Ǐ-2 agonists (brimonidine 0’1-0,2%), carbonic anhydrase inhibitor 
(acetazolamide, dorzolamide) and panretinal photocoagulation. If failed, the other 
method of treatment has to be applied such as (i) trabeculectomy with antimetabolites 
as a first step when there is potential to improve state, (ii) aqueous shunt implants as a 
second step, and (iii) diode laser cyclophotocoagulation or retinal cryoablation , and in 
the worst case, with no vision and the patient suffering from great pain, (iv) 
evisceration or enucleation should be considered (Sivak-Callcott et al., 2001); 
 Grid-pattern laser photocoagulation. According to CVOS study, these procedures have 
no beneficial effect on the visual outcome in macular edema due to CRVO, either 
ischemic or non-ischemic; 
 Scatter panretinal laser photocoagulation. It has been almost universally accepted that 
prophylactic panretinal photocoagulation (PRP) is the treatment of choice to prevent 
neovascular glaucoma or treat neovascular glaucoma itself in ischemic CRVO. CVOS 
study revealed that there is no benefit of the prophylactic PRP in the eyes with ischemic 
CRVO. These results have led to the recommendation that PRP should be applied 
promptly after the identification of intraocular neovascularization in eyes with ischemic 
CRVO to minimize the risk of the development of neovascular glaucoma; 
 Corticosteroids. Steroids reduce vascular permeability and stabilize the blood-retina 
barrier. The mechanism for these effects involves inhibition of the production of 
inflammatory mediators and vascular permeability factors (e.g. VEGF) as well as the 
stabilization of the vascular endothelial cell tight junctions. The inhibition of VEGF 
production may further help prevent neovascular sequelae. Some authors have 
proposed for some patients the systemic use of corticosteroids (Hayreh, 2010) in high 
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oral doses of about 80 mg of prednisone to control macular edema, which is the main 
cause of visual loss. Most of the patients with CRVO according to the SCORE study 
respond to intravitreal triamcinolone application of either 1 or 4 mg doses compared to 
the standard care in terms of improving visual acuity of more than 15 letters. As far as 
the safety is concerned, there are more complications such as cataract formation and 
IOP elevation in the triamcinolone group. Complications rate is higher in the group 
with higher dose (4 mg) (Ip et al., 2009). Although triamcinolone is a long lasting 
corticosteroid, it appears that it is not enough and it leads to the development of 
sustained corticosteroid delivery devices, which release the drug longer. One of them is 
Retisert which has good results in chronic refractory CME (Ramchandran et al., 2008), 
with the best results 12 month after injection. However, the complication rates are very 
high - all phakic eyes developed visually significant cataracts, and 92% have had an 
elevation of IOP that needed intervention. Allergan conducted an international study 
on dexamethasone sustained delivery devices (Ozurdex) and the six month results have 
been published. In CRVO subgroup of patients a significantly better result in gaining 
visual acuity (more than 15 letters) has been recorded in the group which received 0.7 
mg implant compared with control group at 30 and 60 days control point, and not 
significantly better at 90 and 180 days point. There were no significant differences in 
cataract formation between groups and ocular hypertension occurred in only 4% of 
patients receiving an implant. In 2009 FDA gave approval for the Ozurdex in the 
treatment of macular edema secondary to CRVO; 
 Intravitreal anti vascular endothelial growth factor (anti-VEGF). As VEGF plays a key role 
in the pathophysiology of CRVO, several anti-VEGF treatments have been developed to 
decrease VEGF and block vascular permeability and angiogenic activity (bevacizumab, 
ranibizumab, pegaptanib). According to the results of CRUISE study, FDA released 
approval of intravitreal ranibizumab for the treatment of CRVO (Brown et al., 2010); 
 In cases of refractory CME secondary to CRVO with no resolution after bevacizumab or 
IVTA individually, a combination treatment with both agents may result in resolution 
of CME and significant recovery of visual acuity (Ehlers & Fekrat, 2011; Ekdawi & 
Bakri, 2007). These results suggest that for some patients, the complementary actions of 
bevacizumab and IVTA on VEGF and inflammation may be more effective than either 
therapy used alone in the treatment of RVO. Further studies examining multi-modal 
therapy are needed to answer these questions regarding optimal therapy. Probably a 
combined treatment or new drugs will have a better efficacy. 
4. Ocular Ischemic Syndrome 
Obstructions more proximal to the central retinal artery usually cause a more chronic form of 
visual problem – the ocular ischemic syndrome. Ocular ischemic syndrome (OIS) is a 
condition that has a variable spectrum of signs and symptoms that result from chronic ocular 
insufficiency, usually secondary to severe carotid artery disease (CAD). Moreover, they may 
be the first manifestations of CAD (Dugan & Green, 1991). OIS was firstly described in 1963 
and named venous stasis retinopathy (Hedges, 1963; Kearns & Hollenhorst, 1963). 
4.1 Epidemiology 
The OIS occurs at a mean age of 65 years and generally does not develop before 50 years of 
age. Men outnumber women by a ratio of 2:1, because of the higher incidence of 
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atherosclerosis in men (Brown & Magargal, 1988). No racial predilection exists. Bilaterally OIS 
occurs up to 22% of cases (Mendrinos et al., 2010). The incidence of OIS is not known precisely, 
but is estimated at 7.5 cases per million people annually (Sturrock & Mueller, 1984).  
Different studies found various incidence of OIS development in patients with 
hemodynamically significant CAD, which is 4%, 18%, and 1.5% respectively (Kearns & 
Hollenhorst, 1963; Kearns et al., 1978; Klijn et al., 2002). Ipsilateral transient monocular 
visual loss is the hallmark of carotid insufficiency and occurs in 30-40% of patients with 
CAD. CAD on the one common (CCA) or internal carotid artery (ICA) is often accompanied 
by occlusion or stenosis of the opposite carotid artery (Mendrinos et al., 2010). 
4.2 Pathophysiology and causes 
Both stenosis and occlusion of the common or internal carotid arteries are responsible for 
ipsilateral ocular signs and symptoms that may herald a devastating cerebral infarction 
(Biousse, 1997). The decreased vascular perfusion results in tissue hypoxia and increased 
ocular ischemia, leading to neovascularization (Leibovitch et al., 2009; Kahn et al., 1986; 
Takaki et al., 2008). 
Patients who develop OIS show decreased blood flow in the retrobulbar vessels and reversal 
of blood flow in the ophthalmic artery (OA) (Mendrinos et al., 2010). OA shunts blood flow 
away from the eye to the low-resistance intracranial circuit. This blood steal leads to further 
reduction of retrobulbar blood flow, hypoperfusion, and subsequently ocular ischemia.  
OIS develops especially in patients with poor collateral circulation between the internal and 
external arterial systems or between the two ICAs. The occurrence of cerebral infarctions 
and poor neurologic prognosis could also be explained by the insufficient collateral 
circulation.  
4.3 Clinical presentation 
Ocular ischemic syndrome encompasses a spectrum of ocular signs and symptoms that are 
the result of ocular hypoperfusion caused by severe carotid artery obstruction.  
4.3.1 Symptoms 
The presenting symptom is a variable degree of visual loss often accompanied by pain 
caused either by ischemia of the globe or elevated intraocular pressure in neovascular 
glaucoma. The natural course of the ischemic syndrome is generally poor, although there is 
certain proportion of cases with milder clinical picture retaining the visual function. 
4.3.2 Signs 
The anterior segment signs are often present: neovascularization of the iris in approximately 
two thirds of eyes at the time of initial examination; corneal edema and striae usually 
concurrent with increased pressure from neovascular glaucoma. Although the iris 
neovascularization is the presenting sign in large percentage of patients with ischemic 
syndrome, only one third of cases develop secondary neovascular glaucoma. This may be 
due to a lower arterial supply of the ciliary body causing hypotony or normal pressure in 
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spite neovascular changes in the iridocorneal angle. There may be signs of mild anterior 
chamber reaction in 20% of these eyes with flare being a more prominent feature than the 
cellular response (Kahn et al., 1986). Advanced lens opacification may also be present in the 
late stages of this syndrome. The fundoscopic findings may mimic other vascular retinal 
disorders and involutive changes seen in elderly population: constriction, straightening and 
narrowing of the arteries, dilated retinal veins, but without accentuated tortuosity 
commonly seen in vein occlusions. Venous beading may resemble features of proliferative 
diabetic retinopathy. In the majority of cases there are dot and blot retinal hemorrhages 
distributed diffusely around the periphery, but they can spread onto the posterior pole. The 
other features of retinal ischemia may also be present: cherry red spot appearance, cotton 
wool exudates, optic atrophy and edema. 
4.4 Evaluation and imaging 
A careful clinical examination and lab tests (ESR, CRP) must be undertaken to exclude 
possible temporal arteritis, which may resemble this clinical entity and mandates different 
diagnostic and therapeutic approach, which may prevent further visual loss and potentially 
blindness. 
4.4.1 Fluorescein and indocyanine green angiography 
Besides clinical examination, fluorescein angiography (FA) can help to establish the diagnosis 
of ocular ischemic syndrome. Prolonged choroidal filling time is the most specific 
angiographic sign of ocular ischemic syndrome (Mendrinos et al., 2010). Patchy filling of the 
choroid that lasts more than 5 seconds is seen in about 60% of eyes affected by ocular ischemic 
syndrome (Brown & Margargal, 1998). Staining of the retinal vessels, both the major vessels 
and its branches, is another sign seen in 85% of eyes with ocular ischemic syndrome. 
Demonstration of a well-demarcated leading edge of fluorescein dye within a retinal artery is a 
typical sign of OIS. Other findings on fluorescein angiography include an increased 
arteriovenous transit time (over 11 seconds), macular edema, retinal capillary nonperfusion, 
and evidence of microaneurysms (especially in the periphery) (Richard et al., 1998). 
Indocyanine green angiography (ICG) shows signs of choroidal hypoperfusion – occlusion 
of choriocapillaries with filling defects in the posterior pole or the mid-periphery. There is 
also prolonged arm to choroid (over 10 seconds) and intrachoroidal circulation time (over 5-
6 seconds). Another characteristic finding is slow filling of the watershed zones of the 
choroids) (Richard et al., 1998). 
4.4.2 Electroretinography 
Electroretinography demonstrates a decrease in both a and b waves in these eyes, which is 
in contrast to the sparing of the a wave found in central retinal artery occlusions (Brown et 
al., 1982). 
It is of paramount role to assess the carotid artery function since the endarterectomy procedure 
reduces the risk of stroke as life threatening consequence and there is some evidence of 
improvement in retinal function viewed through the improvement of a and b waves in 
electroretinography, as well as the normalization of preoperative retrograde ophthalmic artery 
flow shown on Doppler color imaging (Kawaguchi et al., 2001; Story et al., 1995). 
www.intechopen.com
 Retinal Vascular Occlusions 
 
387 
4.4.3 Duplex carotid ultrasonography 
Duplex carotid ultrasonography combines B-mode ultrasound and Doppler ultrasound 
providing the morphologic imaging and flow velocity data. It is the most commonly used 
noninvasive method in evaluation of carotid artery obstruction. 
Color Doppler imaging is a noninvasive tool for assessing the velocity of blood flow in the 
retrobulbar circulation. Diminished velocities of the blood flow in the central retinal artery, 
choroidal vessels, and ophthalmic artery are typical. There may be a reversal of flow in the 
ophthalmic artery, as well. Color Doppler imaging may assess the carotid arteries 
simultaneously.  
4.4.4 Invasive diagnostics 
If noninvasive carotid artery evaluation is unremarkable in an eye that shows signs 
suggestive of ocular ischemia, conventional carotid arteriography or digital subtraction 
angiography may be required to detect possible chronic obstruction of the ophthalmic artery 
(Wardlaw et al., 2006).  
The new minimally invasive methods, magnetic resonance angiography and computed 
tomographic angiography are evolving and improving as adjunctive diagnostic tests in 
evaluating the patients with carotid occlusive disease.  
4.5 Differential diagnostic 
Diabetic retinopathy 
Nonischemic central retinal venous occlusions 
Giant cell arteritis 
Takayasu arteritis 
Ischemic optic neuropathy 
Retinal artery occlusion 
Neovascular glaucoma 
4.6 Management 
Management of OIS is basically multidisciplinary and the task of the ophthalmologist is to 
treat ocular condition, recognize the possible cause of OIS and refer the patient to a 
cardiologist, neurologist or other specialists, where they can get proper treatment of the 
cause of OIS. 
Ophthalmology treatment consists of increased IOP control, management of 
neovascularization and control of anterior segment inflammation. 
 Anterior segment inflammation is usually treated with topical steroids and long acting 
cycloplegic agents; 
 Increased IOP, usually controlled with topical ǐ-adrenergics blockers, ά-agonists and 
topical or oral carbonic anhydrase inhibitors to reduce aqueous production; 
prostaglandins (could increase ocular inflammation) and pilocarpin should be avoided; 
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 Ocular neovascularization following carotid occlusive disease is usually managed with 
panretinal photocoagulation and can prevent neovascular glaucoma (Carter, 1984; Chen 
et al., 2001). If PRP is not possible due to media opacities or refractory miosis, other 
modalities such as transconjunctival cryotherapy of peripheral retina or transscleral 
diode laser retinopexy should be considered to prevent neovascularization. In any case, 
PRP works effectively and reduces the iris neovascularization in only 36% of patients 
with OIS (Sivalingam et al., 1991). In other cases it can even get worse (Turut & 
Malthieu, 1986), which suggests that uveal ischemia can induce neovascularization, as it 
is shown on animal model (Hayreh & Baines, 1973). Therefore, in the cases where there 
is retinal ischemia, prophylactic PRP is advisable. Neovascularization and macular 
edema caused by OIS can be also treated with intravitreal bevacizumab (Amselem et al., 
2007). In this case report neovascularization regressed, but there was no improvement 
in VA or IOP. Macular edema can also be treated with triamcinolone intravitreally, 
reducing macular edema and improving visual acuity (Klais & Spaide, 2004). Further 
investigation with a more reliable sample is needed to establish the role of this therapy 
in IOS patient. Additionally, we have to mention that when neovascular glaucoma 
occurs it is usually refractory to medical therapy and if panretinal photocoagulation 
failed the other method of treatment has to be applied, such as (i) trabeculectomy with 
antimetabolites as a first step when there is potential to improve state, (ii) aqueous 
shunt implants as a second step, and (iii) diode laser cyclophotocoagulation or retinal 
cryoablation, and in the worst case, with no vision and the patient suffering from great 
pain (iv) evisceration or enucleation should be considered (Sivak-Callcott et al., 2001). 
Medical treatment includes conservative treatment by other specialists in order to manage 
associated systemic diseases or states such as coronary artery disease, hiperlipidemia, 
hypertension, diabetes mellitus etc. 
Some of the surgical treatment is advocated to manage carotid stenosis and to improve ocular 
ischemia (Costa et al. 1999; Chaer & Makaroun, 2008; Sivalingam et al., 1991), such as carotid 
artery endarterectomy (CEA), carotid artery stenting (CAS) or extracranial-intracranial arterial 
bypass surgery (EC-IC), but without sufficient evidence to claim improvement of the ocular 
state with this treatment, except for CEA, where studies show some beneficial effect on the 
patient who has mild ocular ischemia and less effect on the patient with a greater degree of 
ocular ischemia, where retinal damage has probably become irreversible. 
In conclusion, we can say that the ocular ischemic syndrome is a rare, vision-threatening 
condition and since the ophthalmologists may be the first to deal with such patients, they 
should be aware of the clinical presentation of OIS and recognize it early enough to start 
treating the condition when visual acuity is preserved enough and when prognosis is better. 
The continuing improvements in the diagnostic techniques, medical management and surgical 
treatment of carotid artery occlusive disease make the role of ophthalmologists increasingly 
important in the early detection and management of the OIS and its comorbidity. 
5. Conclusion 
Retinal vascular occlusions are an important cause of visual loss, particularly in elderly patients 
with multifactorial pathophysiological arms uniquely intertwined in each patient. They are 
often referred to as a „stroke“in the eye due to symptoms and clinical picture, often dramatic in 
its presentation. It also emphasizes the tremendous influence on patient's quality of life. 
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Apart from the similar clinical symptoms of visual loss there are some distinctive features 
that direct the clinician towards the diagnosis of arterial or venous occlusion. A thorough 
examination should assess the degree of vision loss by testing visual acuity, the presence of 
afferent pupillary defect, visual field testing, slit lamp examination of both anterior and 
posterior segments of the eye as well as ERG, which along with afferent pupillary defect and 
visual field testing provides the most sensitive diagnostic test in distinguishing between 
ischemic and non ischemic types of the occlusive disease (Hayreh, 2005). Visual acuity alone 
is not sufficient to validate peripheral retinal function but solely central vision. Therefore, it 
has been advocated by some authors to combine morphologic and functional tests in order 
to establish the type of the occlusion which has tremendous impact on the clinical course, 
prognosis and management of each case. The oxymetry (Gehlert et al., 2010) offers new 
possible tool in evaluating the perfusion status of the retina as this is extremely important 
prognostic factor when deciding which diagnostic and therapeutic algorithm should be 
undertaken in patient with occlusive disorder. 
In conclusion we can say that retinal vascular occlusions are very common ocular diseases 
and the causes of visual loss with poor perspectives in the past, but recent studies on 
various medications and treatment modalities raise hope between a patient and 
ophthalmologist for establishing the proper treatment. Although we still cannot foresee, 
prevent, or causatively and successfully treat occlusive diseases of the retina, there are 
promising, recently introduced novel options focused on the management of visually 
deteriorating complications. Intravitreal agents, especially anti-VEGF medications and 
intravitreal corticosteroid implants have drastically changed the visual outcome for the 
affected patients. The perspective looks brighter as the development of the most effective 
treatment regimens and their combinations is evolving. Probably a combined therapy will 
better act than a single one. Developing new drugs is warranted. 
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